Link to view presentation: Webcast Link - LD Micro Invitational XVI. Mr. Hoffman will be available for one-on-one meetings with conference attendees. To request a meeting to discuss the Company’s ...
NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of CytoDyn Inc. (OTC: CYDY) between March 27, 2020 and March ...
We are optimistic about the potential of the Company’s lead candidate Cytolin, which is a monoclonal antibody targeting CD11a, a subunit of adhesion molecule LFA-1, which is involved in the process of ...
VANCOUVER, Washington, April 22, 2026 (GLOBE NEWSWIRE)-- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized ...
VANCOUVER, Washington, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential ...
The research being presented at AACR reflects the growing body of scientific work examining CCR5 biology and its role in the tumor microenvironment. Together, these studies help deepen our ...
NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against CytoDyn, Inc. ("CytoDyn” or "the Company") ...
An announcement from CytoDyn ( (CYDY)) is now available. On April 30, 2026, CytoDyn planned to host an investor call and webcast to deliver a corporate and clinical update centered on its leronlimab ...
We are optimistic about the potential of the Company’s lead candidate Cytolin, which is a monoclonal antibody targeting CD11a, a subunit of adhesion molecule LFA-1, which is involved in the process of ...
CytoDyn Inc. Annual stock financials by MarketWatch. View the latest CYDY financial statements, income statements and financial ratios.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results